First-Line Radiotherapy for Colorectal Cancer Liver Metastases

Adding selective internal radiotherapy to chemotherapy failed to improve survival and increased risk for adverse events.

Selective internal radiotherapy with yttrium-90 resin microspheres (SIRT) has proven beneficial as a third-line or subsequent therapy for patients with colorectal cancer (CRC) liver metastases. To determine the potential benefit of adding SIRT to first-line chemotherapy in this setting, investigators conducted a planned pooled analysis of three industry-sponsored, multicenter, open-label, randomized trials involving more than 1100 patients with liver-predominant metastatic CRC.

Most patients were male (66%) and had colon primaries (71%–76%), synchronous metastases (87%), primary tumors in place (50%–55%), and 25% or less liver involvement (68%–69%); a minority had extra hepatic metastases (35%–36%). Patients received first-line FOLFOX chemot…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

First-Line Radiotherapy for Colorectal Cancer Liver Metastases

Topics

Reviewing Author